Literature DB >> 944738

The effect of corticosteroids on human IgG synthesis.

R McMillan, R Longmire, R Yelenosky.   

Abstract

The effect of prolonged, high-dose corticosteroid therapy on total IgG synthesis rates by human bone marrow and splenic leukocytes was studied in patients with immune thrombocytopenia. Marrow IgG production rates begin to decrease 3 weeks after beginning therapy and reach levels approximately one-fourth of pre-treatment rates after 6 weeks. No effect of corticosteroids on splenic IgG production rates could be shown. Marrow IgG synthesis rates in these patients were on the average from 3 to 10 times greater than corresponding splenic production rates and, in addition, appeared to correlate with serum IgG levels. These data suggest that the marrow is an important contributor to the total body IgG pool; and since corticosteroids appear to suppress marrow IgG production, this may be one reason for their therapeutic usefulness in antibody-mediated diseases.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 944738

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  20 in total

Review 1.  Current concepts in the treatment of immune thrombocytopenia.

Authors:  T E Warkentin; J G Kelton
Journal:  Drugs       Date:  1990-10       Impact factor: 9.546

2.  Glucocorticoids administered in vivo inhibit human suppressor T lymphocyte function and diminish B lymphocyte responsiveness in in vitro immunoglobulin synthesis.

Authors:  A Saxon; R H Stevens; S J Ramer; P J Clements; D T Yu
Journal:  J Clin Invest       Date:  1978-04       Impact factor: 14.808

3.  Usefulness of liver infiltrating CD86-positive mononuclear cells for diagnosis of autoimmune hepatitis.

Authors:  Kazutaka Kurokohchi; Tsutomu Masaki; Takashi Himoto; Akihiro Deguchi; Seiji Nakai; Asahiro Morishita; Hirohito Yoneyama; Yasuhiko Kimura; Seishiro Watanabe; Shigeki Kuriyama
Journal:  World J Gastroenterol       Date:  2006-04-28       Impact factor: 5.742

4.  Randomized phase 2 study of FcRn antagonist efgartigimod in generalized myasthenia gravis.

Authors:  James F Howard; Vera Bril; Ted M Burns; Renato Mantegazza; Malgorzata Bilinska; Andrzej Szczudlik; Said Beydoun; Francisco Javier Rodriguez De Rivera Garrido; Fredrik Piehl; Mariarosa Rottoli; Philip Van Damme; Tuan Vu; Amelia Evoli; Miriam Freimer; Tahseen Mozaffar; E Sally Ward; Torsten Dreier; Peter Ulrichts; Katrien Verschueren; Antonio Guglietta; Hans de Haard; Nicolas Leupin; Jan J G M Verschuuren
Journal:  Neurology       Date:  2019-05-22       Impact factor: 9.910

5.  Studies of surface immunoglobulins on human B lymphocytes. III. Physiological variations of SIg+ cells in peripheral blood.

Authors:  T Abo; K Kumagai
Journal:  Clin Exp Immunol       Date:  1978-09       Impact factor: 4.330

6.  The effects of intravenous pulse methylprednisolone on immunological and inflammatory processes in ankylosing spondylitis.

Authors:  M B Richter; P Woo; G S Panayi; A Trull; A Unger; P Shepherd
Journal:  Clin Exp Immunol       Date:  1983-07       Impact factor: 4.330

7.  Corticosteroid enhancement of immunoglobulin synthesis by pokeweed mitogen-stimulated human lymphocytes.

Authors:  D A Cooper; M Duckett; V Petts; R Penny
Journal:  Clin Exp Immunol       Date:  1979-07       Impact factor: 4.330

8.  The effects of prednisolone in leucocyte function in man. A double blind controlled study.

Authors:  J R Clarke; R F Gagnon; F M Gotch; M R Heyworth; I C Maclennan; S C Truelove; C A Waller
Journal:  Clin Exp Immunol       Date:  1977-05       Impact factor: 4.330

9.  Glucocorticosteroid enhancement of immunoglobulin synthesis by pokeweed mitogen-stimulated human lymphocytes. III. Common variable immunodeficiency.

Authors:  D A Cooper; P Hansen; M Duckett; J B Ziegler; R Penny
Journal:  Clin Exp Immunol       Date:  1981-08       Impact factor: 4.330

10.  Muscle hypertrophy and a syndrome of continuous motor unit activity in prednisone-responsive Guillain-Barré polyneuropathy.

Authors:  C Vasilescu; M Alexianu; A Dan
Journal:  J Neurol       Date:  1984       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.